
Opinion|Videos|April 11, 2024
Cost-Effectiveness Metrics Payers Seek for Digital Therapeutics
Diana Brixner, PhD, FAMCP, examines the payer perspective on including Prescription Digital Therapeutics in formularies, utilizing real-world evidence as a key metric to assess the impact, cost-effectiveness, and patient benefit of these innovative digital treatments.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Neffy’s first year: $72.2m in sales, 10,000 schools and broadening payer access
2
Centanafadine hits primary and key secondary endpoints in ADHD phase 3b trial
3
A conversation about vaccines and monoclonal antibodies with Marc Elia, Chairman of Invivyd’s Board of Directors
4
New study confirms benefits of GLP-1 drugs in patients with PAD
5





























